3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Neoplasms
1
Kidney Neoplasms
1
Esophageal Neoplasms
1
Carcinoma, Hepatocellular
1
Interventions
Sorafenib
202
lenvatinib
129
Bevacizumab
124
Nivolumab
85
pembrolizumab
72
atezolizumab
72
Radiosurgery
71
durvalumab
63
Oxaliplatin
59
sintilimab
57
Fluorouracil
54
Doxorubicin
44
tislelizumab
43
apatinib
43
Leucovorin
40
tremelimumab
37
camrelizumab
37
Radiofrequency Ablation
37
Radiotherapy
36
Magnetic Resonance Spectroscopy
32
Capecitabine
30
regorafenib
29
Folfox protocol
29
Cisplatin
28
cabozantinib
26
Hepatectomy
26
Gemcitabine
26
Cyclophosphamide
26
Ipilimumab
25
toripalimab
21
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Carcinoma, Hepatocellular
×
Histocompatibility Testing
×
Clear all
NCT07623265
2026-06-03
IO-MARC
Universitaire Ziekenhuizen KU Leuven
Phase NA
Recruiting
300 enrolled